Disc Medicine, Inc. (NASDAQ:IRON – Free Report) – Analysts at Cantor Fitzgerald raised their FY2025 earnings estimates for Disc Medicine in a research report issued on Wednesday, March 5th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings per share of ($4.59) for the year, up from their previous estimate of ($5.24). The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share.
Disc Medicine (NASDAQ:IRON – Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.08.
Get Our Latest Stock Report on Disc Medicine
Disc Medicine Price Performance
Shares of IRON opened at $55.50 on Friday. Disc Medicine has a 1-year low of $25.60 and a 1-year high of $68.86. The stock has a market cap of $1.65 billion, a PE ratio of -13.94 and a beta of 0.73. The firm has a 50-day simple moving average of $57.33 and a two-hundred day simple moving average of $55.75.
Institutional Trading of Disc Medicine
Several institutional investors have recently modified their holdings of the stock. Sterling Capital Management LLC raised its position in Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock valued at $36,000 after purchasing an additional 503 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in Disc Medicine in the 4th quarter valued at $40,000. Tower Research Capital LLC TRC raised its position in Disc Medicine by 47.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock valued at $52,000 after purchasing an additional 266 shares during the last quarter. Quest Partners LLC purchased a new stake in Disc Medicine in the 3rd quarter valued at $131,000. Finally, Quantbot Technologies LP purchased a new stake in Disc Medicine in the 3rd quarter valued at $146,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.
Insider Buying and Selling
In other news, insider Pamela Stephenson sold 3,137 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total transaction of $171,217.46. Following the completion of the sale, the insider now owns 69,529 shares in the company, valued at approximately $3,794,892.82. The trade was a 4.32 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John D. Quisel sold 12,791 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $66.01, for a total transaction of $844,333.91. Following the sale, the chief executive officer now owns 72,065 shares of the company’s stock, valued at $4,757,010.65. This represents a 15.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 74,080 shares of company stock worth $4,523,520 over the last 90 days. 4.24% of the stock is owned by insiders.
About Disc Medicine
Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Featured Articles
- Five stocks we like better than Disc Medicine
- What Are Dividend Champions? How to Invest in the Champions
- Warren Buffett Swaps VOO for This Reliable Dividend Stock
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Palantir Bears Sell the Headlines—Time for Bulls to Buy?
- How to trade penny stocks: A step-by-step guide
- 3 Beaten Down Stocks With Quality Fundamentals and Outlook
Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.